HRT and breast cancer risk: A realistic perspective

Climacteric

Volumn 14, Issue 6, 2011, Pages 633-636

  Stevenson, J C ^a   Hodis, H N ^b   Pickar, J H ^c   Lobo, R A ^c  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

breast cancer; hormone replacement therapy; risk

Indexed keywords

ACETYLSALICYLIC ACID; BETA CAROTENE; CALCIUM; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; FENOFIBRATE; PLACEBO; RALOXIFENE; ROSIGLITAZONE;

BREAST CANCER; BREAST EXAMINATION; BREAST SELF EXAMINATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; DRUG FATALITY; DRUG INDUCED CANCER; DRUG SURVEILLANCE PROGRAM; FOLLOW UP; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; LUNG CANCER; MAMMOGRAPHY; MENOPAUSAL SYNDROME; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; STROKE; SUDDEN DEATH; VALIDITY; WOMEN'S HEALTH;

BIAS (EPIDEMIOLOGY); BREAST NEOPLASMS; FEMALE; HORMONE REPLACEMENT THERAPY; HOT FLASHES; HUMANS; INCIDENCE; OSTEOPOROSIS, POSTMENOPAUSAL; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT;

EID: 81755162334     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2011.590618     Document Type: Review

References (23)

1. Chlebowski RT, Anderson GL, Gass M, et al . Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010;304:1684-92
2. Stevenson JC, Hodis HN, Pickar JH, Lobo RA. Coronary heart disease and menopause management: the swinging pendulum of HRT. Atherosclerosis 2009;207:336-40
3. Chlebowski RT, Hendrix SL, Langer RD et al. Infl uence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. JAMA 2003;289:3243-53 (Pubitemid 37430077)
4. Rossouw JE, Prentice RL, Manson JE, et al . Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77 (Pubitemid 46556472)
5. Anderson GL, Chlebowski RT, Rossouw JE et al. Prior hormone therapy and breast cancer risk in the Women ' s Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55:103-15 (Pubitemid 44307491)
6. Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer 2004;101:1490-500 (Pubitemid 39318893)
7. Li CI, Malone KE, Porter PL, et al . Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. Cancer Epidemiol Biomarkers Prev 2008;17:43-50 (Pubitemid 351196272)
8. Chlebowski RT, Kuller LH, Prentice RL, et al . Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009;360:573-87
9. Schuetz F, Diel IJ, Pueschel M et al. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy. Am J Obstet Gynecol 2007;196:342 e1 - 9
10. S ener SF, Winchester DJ, Winchester DP et al. The effects of hormone replacement therapy on postmenopausal breast cancer biology and survival. Am J Surg 2009;197:403-7
11. Salpeter SR, Walsh JM, Greyber E et al. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med . 2004;19:791-804 (Pubitemid 38951954)
12. Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med 2009;122:1016-22
13. Salpeter SR, Buckley NS, Liu H, Salpeter EE. The cost-effectiveness of hormone therapy in younger and older postmenopausal women. Am J Med 2009;122:42-52
14. Stefanick ML, Anderson GL, Margolis KL, et al . Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647-57
15. LaCroix A, Chlebowski R, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305-14
16. Bluming AZ, Tavris C. Hormone replacement therapy: real concerns and false alarms. Cancer 2009;15:93-104
17. Barrett-Connor E, Mosca L, Collins P, et al .; Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37 (Pubitemid 44050394)
18. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians ' Health Study Research Group. N Engl J Med 1989;321:129-35
19. Keech A, Simes RJ, Barter P, et al . FIELD study investigators. Effects of long-term fenofi brate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366: 1849-61
20. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, et al . Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304:411-18
21. Omenn GS, Goodman GE, Thornquist MD et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5 (Pubitemid 26137973)
22. Bolland MJ, Avenell A, Baron JA et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010;341:c3691
23. Bolland MJ, Barber PA, Doughty RN et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 2008;336:262-6 (Pubitemid 351251627)